Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | TAS1R3 | Q7RTX0 | 6/20 | 0.42 |
| ▸ | TAS1R1 | Q7RTX1 | 6/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | GRN | P28799 | 2/20 | 0.41 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.40 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.40 |
| ▸ | TACR3 | P29371 | 1/20 | 0.40 |
| ▸ | FNTA | P49354 | 1/20 | 0.39 |
| ▸ | FNTB | P49356 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5420297 | 1.00 | PYGL (0.48) | PYGLCYP2C9TAS1R3TAS1R1KDR | |
| SCHEMBL5218743 | 0.87 | TAS1R3 (0.48) | PYGLCYP2C9TAS1R3TAS1R1KDR | |
| SCHEMBL5192355 | 0.87 | TAS1R3 (0.42) | PYGLCYP2C9TAS1R3TAS1R1KDR | |
| SCHEMBL5427980 | 0.86 | PYGL (0.50) | PYGLTAS1R3TAS1R1KDRIDO1 | |
| SCHEMBL5427982 | 0.86 | PYGL (0.50) | PYGLTAS1R3TAS1R1KDRIDO1 | |
| SCHEMBL5214636 | 0.86 | TAS1R3 (0.49) | PYGLCYP2C9TAS1R3TAS1R1KDR | |
| SCHEMBL5214631 | 0.86 | TAS1R3 (0.49) | PYGLCYP2C9TAS1R3TAS1R1KDR | |
| SCHEMBL5417856 | 0.85 | NPSR1 (0.41) | TAS1R3TAS1R1KDRKMT2A | |
| SCHEMBL5424475 | 0.85 | TAS1R3 (0.50) | PYGLCYP2C9TAS1R3TAS1R1KDR | |
| SCHEMBL5424479 | 0.85 | TAS1R3 (0.50) | PYGLCYP2C9TAS1R3TAS1R1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249670-A1 | Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249670-A1 | Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof | PYGM, PYGL, GYS1 | PYGL 2/4885CYP2C9 2982/4885TAS1R3 4821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.